CAH StripAssay®

The CAH StripAssay® offered by Oasis Diagnostics Corporation is a cost effective tool for the confirmation of Congenital Adrenal Hyperplasia (CAH) early in the disease cycle to to minimize emotional stress for parents and economic burden. Neonatal 17-OHP testing is highly susceptible to false positive results, making genetic testing an important confirmatory tool for early and reliable CAH diagnosis. The CAH StripAssay® is based on detection of the CYP21A2 gene in dry blood samples.

CAH StripAssay® Brochure

• Kits are based on reverse-hybridization of biotinylated PCR products.
• Minimal equipment required (thermal cycler, shaking water bath).
• Technology combines probes for mutations and controls in a parallel array of allele-specific oligonucleotides.
• Functions using immobilized oligos on a teststrip.
• Strips show mutations by enzymatic color reaction visible to the naked eye.
• Proprietary software package (Evaluator™) that aids in data interpretation, storage, and archiving.

Publications

Molecular Analysis of CYP21A2 Gene Mutations among Iraqi Patients with Congenital Adrenal Hyperplasia (2016 Al-Obaidi)

Reverse-hybridization assay for rapid detection of common CYP21A2 mutations in dried blood spots from newborns with elevated 17-OH progesterone (Németh 2012)

Mutations Detected

CAH StripAssay® Catalog 4-380

P30L

I2 splice (I2 G)

Del 8 bp E3 (G110del8nt)

I172N

Cluster E6 (I236N, V237E, M239K)

V281L

L307 frameshift (F306+T)

Q318X

R356W

P453S

R483P